Experienced research scientist provides scientific support for patent prosecution and counseling
Skyla A. Duncan, PhD focuses on US and foreign patent prosecution in the life science area. Skyla will assist our team with patent applications, prosecution, diligence, and other counseling matters by evaluating the underlying technology of inventions. Skyla is also pursuing her certification as a patent agent.
Prior to joining McNeill Baur PLLC, Skyla completed a postdoctoral research fellowship at
Memorial Sloan Kettering Cancer Center in molecular pharmacology, studying the pharmacologic
tractability of ceramide rich platform-mediated CD28 co-stimulation for advanced T cell activation
and proliferation. She performed extensive independent research employing techniques such as
confocal immunohistology, 2D and 3D confocal assays, ceramide inhibition and augmentation
assays, cell proliferation (viability and cytoxicity) assays such as MTT assays and LIVE/DEAD cell
sStaining, cloning/protein expression, Taqman™ qRT-PCR, single ELISAs, flow cytometry, animal, and
cell culture work.
Previously, she completed her PhD at Alabama State University in the field of Microbiology
(dual focus in Immunology and Nanotechnology) at the Center of NanoBiotechnology Research
Center (CNBR). Her research focused on delineating the mechanisms associated with the regulatory
role of SOCS proteins in the Interleukin-10 control of Chlamydia pathogenesis as well as
encapsulating Interleukin-10 in pegylated nanoparticles to harness and prolong its therapeutic effects for treatment of Chlamydial disease. She employed several bioinstrumentation techniques for these projects include animal work, human and mammalian cell culture and proper infectivity, cloning/protein expression, protein purification, RNA purification, DNA purification, Taqman™ qRT-PCR, multiplex and single ELISAs, confocal microscopy, flow cytometry, CRISPR gene editing,
formulation, production, purification, and quantification of nanoparticles, imaging, zetasizer, zeta
potential, and numerous biostatistics and data programs.
Skyla is also involved with several life science organizations including the American Society
of Microbiology, American Association of Immunologists, Chlamydia Basic Research Society,
Beta Kappa Chi Honor Society, Earl Lester Cole Honor Society, and the Alpha Lambda Delta
“Suppressors of Cytokine Signaling (SOCS) Proteins as Potential Mediators of Interleukin-10
Modulation of Inflammatory Responses Induced by Live Chlamydia muridarum and its
Major Outer Membrane Protein (MOMP) in Mouse J774 Macrophages,” Mediators of
“Prolonged Release and Functionality of Interleukin-10 Encapsulated within PLA-PEG
Nanoparticles,” Nanomaterials 9(8):1074 (2019).
“SOCS Proteins as Regulators of Inflammatory Responses Induced by Bacterial Infections: A
Review,” Frontiers in Microbiology 8(2431) (2017).
“A Nanovaccine Formulation of Chlamydia Recombinant MOMP Encapsulated in PLGA
85:15 Nanoparticles Augments CD4+ effector (CD44high CD62Llow) and Memory
(CD44high CD62Lhigh)T Cells in Immunized Mice,” Nanomedicine 102257 (2020)
“The Chlamydia M278 Major Outer Membrane Peptide Encapsulated in the Poly(lactic
acid)-Poly(ethylene glycol) Nanoparticulate Self-Adjuvanting Delivery System Protects Mice
Against a Chlamydia muridarum Genital Tract Challenge by Stimulating Robust Systemic
and Local Mucosal Immune Responses,” Frontiers in Immunology 9:2369 (2018)
“Interleukin-10 Conjugation to Carboxylated PVP-Coated Silver Nanoparticles for Improved
Stability and Therapeutic Efficacy,” Nanomaterials 7(7):165 (2017) (coauthor).
“Caveolin-Mediated Endocytosis of the Chlamydia M278 Outer Membrane Peptide
Encapsulated in Poly(lactic acid)-Poly(ethylene glycol) Nanoparticles by Mouse Primary
Dendritic Cells Enhances Specific Immune Effectors Mediated by MHC Class II and CD4+ T
cells,” El Sevier 159:130-145 (2018) (coauthor).
"Future of human Chlamydia vaccine: Potential of self-adjuvanting biodegradable
nanoparticles as safe vaccine delivery vehicles," Expert Rev Vaccines 17(3):217-227 (2018)